Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
Renata Medical, a California-based healthcare technology company, has gained U.S. Food and Drug Administration (FDA) approval for a new stent specifically designed for pediatric patients with congenital heart defects. The Minima Growth Stent was built to treat newborns, infants and young children, and then it continues to expand as the patient ages

FDA approves new expanding stent for young children

The new interventional device from Renata Medical is designed to expand as young patients age, providing long-term relief. 

Boston Scientific TAVR ACURATE Prime Aortic Valve System

Boston Scientific’s new TAVR valve gains CE mark approval

The self-expanding Acurate Prime Aortic Valve System was designed with improved valve positioning in mind. According to Boston Scientific, it it will be available in more sizes than the company's previous TAVR device to ensure it can treat as many heart patients as possible. 

TCT 2023 crowd

CRF announces late-breaking clinical trials for TCT 2024

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more. 

Pedro Martinez Clark, MD, is helping to addressing health disparities and high PAD and CLI rates in Latin and Haitian communities in Miami.

Addressing high PAD and CLI rates in Latin and Haitian communities of Miami

Pedro Martinez Clark, MD, FSCAI, interventional cardiologist, medical director of Amavita Heart and Vascular Health in Miami, set up community outreach efforts to screen patients in low-income neighborhoods.
 

cardiologist viewing heart data

TAVR and SAVR linked to comparable long-term outcomes, new meta-analysis confirms

Researchers combined data from three well-known clinical trials—NOTION, Evolut Low Risk and PARTNER 3—and evaluated thousands of low-risk patients who presented with severe aortic stenosis. 

Treating atrial functional mitral regurgitation (AFMR) with surgery may be more beneficial than medical therapy alone, according to new data published in JAMA Network Open.[1]

Atrial functional mitral regurgitation: Surgery improves outcomes more than medical therapy alone

"These findings underscore the importance of understanding AFMR and its treatment options," one cardiologist said.

Interventional cardiologists in Canada have performed the world’s first implant of a new coronary sinus reducer designed to treat chest pain patients who see no benefits from other available interventional or surgical treatments. The A-Flux Reducer System was designed and developed by VahatiCor, a new medical device company associated with California-based T45 Labs.

Cardiologists detail world’s first implant of new device for ‘no-option’ chest pain patients

The A-Flux Reducer System by VahatiCor was designed to “conform seamlessly” to any patient’s anatomy, and it can be repositioned or retrieved as necessary.

V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.

Johnson & Johnson to acquire heart failure specialists V-Wave for up to $1.7B

V-Wave has gained considerable attention for its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and lungs of HFrEF patients.

Displaying 81 - 88 of 973
Design by Adaptive Theme